Peptide Resources
⚠️ Research Disclaimer: Many peptides listed below (e.g., BPC-157, TB-500, Epitalon) are classified as "Research Chemicals" and are not FDA-approved for human therapeutic use. Approved peptides (e.g., Semaglutide, Tirzepatide) are indicated only for specific medical conditions. This archive is for educational and informational purposes only.
1. Metabolic & Weight Loss (Incretin Mimetics)
Semaglutide
GLP-1 Receptor Agonist.
-
Mechanism: Mimics Glucagon-Like Peptide-1 to increase insulin secretion, lower glucagon, and delay gastric emptying.
-
Key Study: The STEP Trials (STEP 1-5).
-
Finding: 2.4mg weekly resulted in ~15% body weight loss over 68 weeks. Reduced major adverse cardiovascular events (MACE) in select populations.
-
-
Status: FDA Approved (Ozempic/Wegovy).
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist.
-
Mechanism: Activates both GIP and GLP-1 receptors, enhancing insulin sensitivity and fat utilization more potently than GLP-1 alone.
-
Key Study: SURMOUNT-1.
-
Finding: 15mg weekly resulted in ~21% body weight loss. Superior efficacy to Semaglutide in head-to-head trials (SURPASS).
-
-
Status: FDA Approved (Mounjaro/Zepbound)
Retatrutide
Triple Agonist (GLP-1, GIP, Glucagon).
-
Mechanism: Adds Glucagon receptor agonism (GCGR) to the mix, which increases energy expenditure (burning calories) alongside appetite suppression.
-
Key Study: Phase 2 Trial (NEJM 2023).
-
Finding: Participants achieved up to 24.2% weight loss at 48 weeks. It is currently the most potent weight loss agent in late-stage development.
-
Note: Higher heart rate increases observed compared to dual agonists due to glucagon activity.
-
2. Healing, Repair & Tissue Regeneration
BPC-157
Pentadecapeptide (Gastric derivative).
-
Mechanism: Upregulates Growth Hormone Receptor (GHR) in tendon fibroblasts; modulates VEGF for angiogenesis (new blood vessels).
-
Key Research: Chang et al. (2011) demonstrated accelerated healing of transected Achilles tendons in rats. Sikiric et al. widely documented its gastroprotective effects against NSAID damage and fistulas.
TB-500 (Thymosin Beta-4 Fragment)
Synthetic fraction of Thymosin Beta-4.
-
Mechanism: Sequesters actin, a protein essential for cell structure and movement. Promotes cell migration to injury sites and prevents fibrosis (scar tissue).
-
Research Context: Studied for cardiac tissue repair after heart attacks and corneal healing. In sports/research, used for muscle tears and flexibility.
Klow Blend
Proprietary "Radiance/Recovery" Blend.
-
Composition: Typically a synergistic mix of BPC-157, TB-500, GHK-Cu (Copper Peptide), and KPV.
-
Mechanism: Combines the soft tissue repair of BPC/TB-500 with the skin-remodeling and anti-inflammatory effects of GHK-Cu and KPV.
-
Use Case: Often marketed for "whole body recovery," post-surgery healing, and aesthetic skin improvement.
3. Growth Hormone & Anabolic Agents
HGH (Human Growth Hormone)
191-amino acid protein.
-
Mechanism: Stimulates liver to produce IGF-1.
-
Research: Gold standard for growth hormone deficiency. FDA approved. Increases muscle mass, reduces fat, improves bone density.
IGF-1 (Insulin-like Growth Factor 1)
Downstream effector of HGH.
-
Mechanism: Directly mediates the cell-growing effects of HGH.
-
Research: Promotes hyperplasia (splitting of muscle cells) rather than just hypertrophy (growth of existing cells).
IGF-1 LR3
Long R3 IGF-1 (Modified Analog).
-
Mechanism: An analog of IGF-1 with an 83-amino acid chain that prevents it from binding to IGF-binding proteins (IGFBPs).
-
Significance: This gives it a significantly longer half-life (~20-30 hours) compared to regular IGF-1 (~15-20 mins), making it much more potent for muscle growth in research settings.